**Project proposal form for extensions to existing Lifecourse GWAS consortium infrastructure**

**Version 1**

Access to the infrastructure generated by the Lifecourse GWAS consortium consortium is available by application to the Lifecourse GWAS consortium steering committee and will be granted to qualified investigators for appropriate use. The infrastructure is defined as: i) the use of the pipeline by extending the current software, ii) extending the scope of the current software to analyse new phenotypes or exposures, iii) dissemination of further analyses to other consortium members. This is also the process by which new analyses that are to be deployed to consortium members will be assessed. Note: Individual-level data collections will be held within each cohort. Access to individual cohorts need to be gained by application to each cohort using their specific procedures.

The Lifecourse GWAS consortium follows the recommendation of the Fort Lauderdale meeting held in January 2003 addressing the roles and responsibilities of data producers, data users, and funders of community resource project. The report from that meeting can be viewed at [FortLauderdale.pdf](http://www.wellcome.ac.uk/stellent/groups/corporatesite/%40policy_communications/documents/web_document/wtd003207.pdf)

Please observe the following guidelines when using data generated through the Lifecourse GWAS consortium infrastructure:

* Data users may use the pipeline and collaborate within the community following approval of proposal by the steering committee. In all written presentations, disclosures, or publications of analyses resulting from such collaboration they are expected to:
* Acknowledge the resource producers by including Lifecourse GWAS consortium investigators as co-authors. For follow-up analyses, an analysts’ group will be formed, including designated members from Bristol as well as those leading the analysis. Any cohorts contributing new analyses will be granted authorship under the same policy as the main paper, as outlined in the Principles of Collaboration document.
* Recognise the funding organisation that supported the work.
* The publication and presentation moratorium are expected to extend to all forms of public disclosure, including meeting abstracts, oral presentations, and formal electronic submissions to publicly accessible sites (e.g., public websites, web blogs).

For further information please contact: grace.power@bristol.ac.uk or eleanor.sanderson@bristol.ac.uk

**Project proposal**

*Submitted to the Lifecourse GWAS consortium: yyyy-mm-dd*

1. Proposed Project overview

Provide a clear and descriptive title for your project.

* Project Title:
* Aim(s):
* Abstract (200 words max):

2. Principal Investigator (PI) and Research Team

Principal Investigator (PI) Name:

Institutional Affiliation:

Email Address:

List of authors/collaborators (please add additional rows if required):

| Name | Role in the Project | Institution | Email Address |
| --- | --- | --- | --- |
| [Author 1] | [e.g., Co-Investigator, Data Scientist] | [e.g., University XYZ] | [author1@email.com] |
| [Author 2] | [e.g., Analyst, Research Assistant] | [e.g., University ABC] | [author2@email.com] |

3. Data Generation Using Lifecourse GWAS Consortium Pipeline

Are you planning to use the Lifecourse GWAS pipeline?

☐ Yes

☐ No

If yes, please describe how your study will use the Lifecourse GWAS pipeline (250 words max):

4. Research Description

Provide a brief summary of your research, including the objectives and specific research question(s) you aim to answer. Please include how your research aligns with the pipeline and why analysing new phenotypes is essential for your project.

Research Summary (500 words max):

5. Overarching theme and phenotypes of interest

Describe the overarching theme of the phenotypes (e.g., psychiatric disorders, cardiovascular health) and list the specific new phenotypes you wish to generate using the pipeline.

Overarching research theme (e.g., psychiatric disorders, metabolic health):

Specific Phenotypes of Interest (please add additional rows if required):

| Phenotype | Brief Description of Importance to Research | Reason for New Data Generation |
| --- | --- | --- |
| [Phenotype 1] | [e.g., Anxiety symptoms] | [e.g., Not covered in existing dataset] |
| [Phenotype 2] | [e.g., Heart rate variability] | [e.g., To explore links to cardiovascular health] |

6. Integration and analytical methods

Explain how you will integrate the newly generated phenotypes with your existing data and the statistical methods, models, or tools you plan to use following the GWAS generation.

Integration plan:

Proposed analytical methods following GWAS generation:

7. Data Use and Sharing Plan

Explain how the newly generated phenotypic data will be used, stored, and shared during and after your analysis.

Data Use and Storage Plan:

Data Sharing (if applicable):

Will data be shared with investigators outside the Lifecourse GWAS consortium?

☐ Yes

☐ No

If yes, specify data type and with whom:

8. Timeline and Dependencies

Provide an estimated timeline for your project.

* Start Date:
* End Date:
* Key Milestones:

Does the project depend on the Lifecourse GWAS consortium team carrying out any analyses ("internal projects")?

☐ Yes

☐ No

If so, provide details:

Does the project rely on unpublished Lifecourse GWAS analyses for additional resources ("external projects")?

☐ Yes

☐ No

If so, provide details:

9. Expected Outcomes and Publications

Describe the expected outcomes from using the newly generated data and how you plan to disseminate your findings (e.g., academic journal, conference presentation, internal report).

Expected Data Output:

Planned Publications or Presentations:

10. Title and Summary for Website

Provide a title and brief summary of your project (150 words max) for the Lifecourse GWAS website.

10. Additional Information or Special Requests

Use this section to include any other relevant information or to make special requests related to the pipeline.

11. Acknowledgment and Data Use Agreement

By submitting this form, you acknowledge and agree to abide by the pipeline-sharing policies stated above associated with the use of this pipeline.

* Name of Principal Investigator:
* Signature (Typed is acceptable):
* Date: